Skip to main navigation menu Skip to main content Skip to site footer

Narrative Review

Vol. 10 No. 2 (2007)

'Miracle stents' - a future without restenosis

  • Huda Hamid
  • John Coltart
November 1, 2020


Over the last three decades, percutaneous coronary intervention (PCI) technology has revolutionized the field of cardiology. PCI began in the form of balloon angioplasty, and was followed by coronary stenting. In-Stent restenosis is the main limitation of coronary stenting, and has been delayed to some extent by the development of drug eluting stents. Coronary angioplasty with stenting is currently the most popular non-medical treatment of coronary artery disease therefore solving the problem of in-stent restenosis could change the future role of other types of coronary intervention. This review examines the types of percutaneous coronary interventions, the mechanisms leading up to in-stent restenosis, and how previous and current treatments of in-stent restenosis influence the vascular response to injury.


  1. Bakhai A, Hill RA, Dundar Y, Dickson R, Walley T. Percutaneous Transluminal Coronary Angioplasty with Stents Versus Coronary Artery Bypass Grafting for People with Stable Angina or Acute Coronary Syndromes. Cochrane Database Syst Rev 2005; (1):CD004588
  2. Reul, RM. Will Drug-eluting Stents Replace Coronary Artery Bypass Surgery? Tex Heart Inst J 2005; 32(3): 323-330
  3. Grech ED. ABC of Interventional Cardiology: Percutaneous Coronary Intervention II: the Procedure. BMJ 2003; 326(73
  4. Ruygrok PN, Serruys PW. (1996). Intracoronary stenting. From concept to custom., Circulation, Sep 1;94(5):882-90.99):1137-40.
  5. Yang XM, Manninen H, Matsi P, Soimakallio S. (1991) Percutaneous endovascular stenting: development, investigation and application. Eur. J. Radiol. Nov-Dec;13(3):161-73.
  6. Mitra AK, Agrawal DK. (2006). In stent restenosis: bane of the stent era. J Clin Pathol. Mar;59(3):232-9.
  7. Faxon DP, Sanborn TA, Haudenschild CC. (1987) Mechanism of angioplasty and its relation to restenosis. Am J Cardiol., Jul
  8. ;60(3):5B-9B
  9. Edelman ER, Rogers C. (1996) Hoop dreams. Stents without restenosis. Circulation. Sep 15;94(6):1199-202.
  10. Stocker R, Keaney JF Jr. (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev. Oct;84(4):1381-478.
  11. Welt FG, Rogers C. (2002) Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. Nov 1;22(11):1769-76.
  12. White CJ, (2005) Drug-Eluting Stents Advanced Applications for the Management of Coronary Disease. Taylor &Francis. pp. 7-11, 15, 19, 22-23, 74.
  13. Schoenhagen P, Ziada KM, Vince DG, Nissen SE, Tuzcu EM. (2001) Arterial remodeling and coronary artery disease: the
  14. concept of "dilated" versus "obstructive" coronary atherosclerosis. J Am Coll Cardiol. Aug;38(2):297-306.
  15. Bennett MR. (2003) In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart, Feb;89(2):218-24.
  16. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. (1994) A
  17. randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease.
  18. Stent Restenosis Study Investigators. N Engl J Med., Aug 25;331(8):496-501.
  19. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al. (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary
  20. artery disease. Benestent Study Group. N Engl J Med. Aug 25;331(8):489-95.
  21. Inoue T, Sakai Y, Hoshi K, Yaguchi I, Fujito T, Morooka S. (1998) Lower expression of neutrophil adhesion molecule
  22. indicates less vessel wall injury and might explain lower restenosis rate after cutting balloon angioplasty. Circulation, Jun
  23. ;97(25):2511-8.
  24. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. (1995) The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost. Jul;74(1):552-9
  25. Rollins BJ. (1996) Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory
  26. disease. Mol Med Today. May;2(5):198-204.
  27. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S. (1999) Anti-monocyte
  28. chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. Feb 19;84(3):306-14.
  29. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, Paloscia L, Materazzo G, D'Annunzio E, Conti P, Chiarelli F,
  30. Cuccurullo F, Mezzetti A. (2001) Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis Vol. 10 No. 2 Miracle Stents 111 after coronary angioplasty. Arterioscler Thromb Vasc Biol. Mar;21(3):327-34.
  31. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. (1995) Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res. Jun;76(6):996-1002
  32. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. (1996) Arterial remodeling
  33. after coronary angioplasty: a serial intravascular ultrasound study. Circulation, Jul 1;94(1):35-43.
  34. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. (1996) Patterns and
  35. mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation, Sep 15;94(6):1247-54
  36. Lafont A, Durand E, Samuel JL, Besse B, Addad F, Levy BI, Desnos M, Guerot C, Boulanger CM. (1999) Endothelial
  37. dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation, Sep 7;100(10):1109-15
  38. Kavanagh CA, Rochev YA, Gallagher WM, Dawson KA, Keenan AK. (2004) Local drug delivery in restenosis injury:
  39. thermoresponsive co-polymers as potential drug delivery systems. Pharmacol Ther. Apr;102(1):1-15
  40. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead
  41. D, Kuntz RE. (2004) Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent
  42. versus a standard stent in patients at high risk for coronary restenosis. Circulation, Feb 10;109(5):634-40
  43. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. (2007) A pooled analysis of data comparing sirolimus-eluting
  44. stents with bare-metal stents. N Engl J Med. Mar 8;356(10):989-97
  45. European Society of Cardiology Congress News. (2006) The drug eluting stents debate – Hot Line Session Results.
  46. September 5, 2006. Accessed
  47. th June, 2007.
  48. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. (2007) Drug-eluting stent and coronary
  49. thrombosis: biological mechanisms and clinical implications. Circulation. Feb 27;115(8):1051-8.
  50. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. (2006) Late thrombosis of drug-eluting stents: a meta-
  51. analysis of randomized clinical trials. Am J Med. Dec;119(12):1056-61.
  52. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip
  53. DE, Fahy M, Pocock SJ, Mehran R, Leon MB. (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
  54. N Engl J Med. Mar 8;356(10):998-1008.
  55. Pasceri V, Patti G, Speciale G, Pristipino C, Richichi G, Di Sciascio G. (2007) Meta-analysis of clinical trials on use of
  56. drug-eluting stents for treatment of acute myocardial infarction. Am Heart J. May;153(5):749-54.
  57. Smith EJ, Jain AK, Rothman MT. (2006) New developments in coronary stent technology. J Interv Cardiol. 2006 Dec;19(6):493-9.
  58. Erbel R, Di Mario C, Bartunek J, et al. (2007) Temporary scaffolding of coronary arteries with bioabsorbable magnesium
  59. stents: a prospective, non-randomised multicentre trial. Lancet. Jun 2;369(9576):1869-75.
  60. Waksman R. (2006) Update on bioabsorbable stents: from bench to clinical. J Interv Cardiol. Oct;19(5):414-21.
  61. Bhargava B, Karthikeyan G, Abizaid AS, Mehran R. (2003) New approaches to preventing restenosis. BMJ. Aug 2;327(7409):274-9.
  62. Abbott Press Release. (2007) Abbott submits XIENCETM V Everolimus Eluting Coronary Stent System Application for U.S. FDA Approval. June 1, 2007. Accessed 19th June 2007.
  63. Mitka M. (2007) New drug-eluting stents under study. JAMA. May 16;297(19):2064-7.


Download data is not yet available.